LENZ Therapeutics

Update in progress

LENZ (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

LENZ Therapeutics, Inc. is a commercial pharmaceutical company focused on developing and marketing therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for treating presbyopia in adults. The company was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. It was founded in 2013 and is headquartered in Solana Beach, California.

Company score

Sentiment: 0.54; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.43; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.15; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.35; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive